SCHEMBL3341323

SCHEMBL3341323

COc1cc(Cl)c(C(=N)NO)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 1/20 0.38
HTR2A P28223 1/20 0.37
SLC6A4 P31645 1/20 0.37
KCNH2 Q12809 1/20 0.37
PYGL P06737 3/20 0.36
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 2/20 0.34
APEX1 P27695 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369806 0.85 GAA (0.40) NPC1MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL5107602 0.77 GAA (0.53) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL2810660 0.75 GAA (0.42) NPC1MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL25851403 0.75 RAB9A (0.48) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL2476566 0.75 RAB9A (0.50) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL14449050 0.73 RAB9A (0.47) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL19088274 0.72 HTR2A (0.44) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL13303921 0.71 GAA (0.47) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL25304330 0.70 GAA (0.53) NPC1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL2326653 0.70 HTT (0.57) MAPTRAB9AALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 NPC1 241/4885MAPT 4318/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.